68Ga Bombesin PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Noncontributory Conventional Imaging
Abstract
Purpose: 68Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (68Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide receptors (GRPr). GRPr proteins are highly overexpressed in several human tumors, including prostate cancer (PCa).Methods: We enrolled 15 men with biochemically recurrent PCa from May to Sep 2017, 63-79 year-old (mean standard deviation(SD): 70.34.3). Imaging started at 41-89 minutes (mean SD: 53.614.1) after injection of 127.5-146.5 MBq (mean SD: 141.04.7)of 68Ga-RM2 using a time-of-flight (TOF)-enabled simultaneous positron emission tomography (PET) / magnetic resonance imaging(MRI) scanner. T1-weighted (T1w), T2-weighted (T2w) and diffusion-weighted images (DWI) were acquired. Results: All patients had rising prostate specific antigen (PSA) (range: 0.2-12.5 ng/mL; mean SD: 4.24.4) and negative CI (CT or MRI, and 99mTc MDP bone scan) prior to enrollment. The observed 68Ga-RM2 PET detection rate was 73.3 . 68Ga-RM2 PET identified recurrent PCa in 11 of the 15 participants.Conclusions: 68Ga-RM2 PET can be used for assessment of GRPr expression in patients with biochemically recurrent PCa. High uptake in multiple areas compatible with cancer lesions suggests that 68Ga-RM2 is a promising PET radiopharmaceutical for localization of disease in participants with biochemically recurrent PCa and negative conventional imaging.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2017
- Accession Number
- AD1045667
Entities
People
- Andrei Iagaru
Organizations
- Stanford University